Skip to main content

Table 2 Healthy donors PBMC T-regulatory cell analysis

From: Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Subject CD4+/CD52hi+Foxp3+% CD4+/CD25hi+/CD39+%
1 83.7 39.3
2 88.2 30.2
3 80.2 76.9
4 88.2 89.0
5 97.7 76.1
6 89.7 69.0
7 95.9 96.7
Average 89.08 68.17